SLNO
The legal cloud just got a little darker
Soleno Therapeutics is back in the headlines for the kind of reason companies hate: a securities class action. Hagens Berman says investors who bought SLNO between March 26, 2025 and November 4, 2025 now have a May 5, 2026 deadline to seek lead plaintiff status.
What’s the beef?
The complaint says Soleno allegedly downplayed safety concerns tied to DCCR, including excess fluid retention and possible heart failure risk in children. If that sounds like a messy clinical narrative, that’s because it is — and investors tend to punish messy narratives faster than a toddler can spill juice.
Why investors should care
This isn’t just legal paperwork collecting dust in a filing cabinet. Securities suits can keep a stock under a microscope, add settlement risk, and drag on sentiment while the company tries to convince Wall Street the underlying business story still works.
There’s also a little extra spice here: the complaint references a short-seller report from Scorpion Capital, which alleged data integrity issues in Soleno’s Phase 3 program. Translation: the market is being asked to judge not just the launch, but the trustworthiness of the whole setup.
Big picture: even when the treatment story is supposed to be about patients, investors often end up reading the footnotes. And right now, Soleno’s footnotes are doing a lot of the talking.